Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 1801344-14-8
2. Emavusertib [inn]
3. Mh5dmf9jky
4. Ca4948
5. Au-4948
6. (r)-n-(5-(3-hydroxypyrrolidin-1-yl)-2-morpholinooxazolo[4,5-b]pyridin-6-yl)-2-(2-methylpyridin-4-yl)oxazole-4-carboxamide
7. Chembl4783351
8. 4-oxazolecarboxamide, N-[5-[(3r)-3-hydroxy-1-pyrrolidinyl]-2-(4-morpholinyl)oxazolo[4,5-b]pyridin-6-yl]-2-(2-methyl-4-pyridinyl)-
9. N-[5-[(3r)-3-hydroxypyrrolidin-1-yl]-2-morpholin-4-yl-[1,3]oxazolo[4,5-b]pyridin-6-yl]-2-(2-methylpyridin-4-yl)-1,3-oxazole-4-carboxamide
10. 2-(2-methylpyridin-4-yl)-n-[2-morpholin-4-yl-5-[(3r)-3-oxidanylpyrrolidin-1-yl]-[1,3]oxazolo[4,5-b]pyridin-6-yl]-1,3-oxazole-4-carboxamide
11. 4-oxazolecarboxamide, N-(5-((3r)-3-hydroxy-1-pyrrolidinyl)-2-(4-morpholinyl)oxazolo(4,5-b)pyridin-6-yl)-2-(2-methyl-4-pyridinyl)-
12. N-(5-((3r)-3-hydroxy-1-pyrrolidinyl)-2-(4-morpholinyl)oxazolo(4,5-b)pyridin-6-yl)-2-(2-methyl-4-pyridinyl)-4-oxazolecarboxamide
13. N-(5-((3r)-3-hydroxypyrrolidin-1-yl)-2-(morpholin-4- Yl)(1,3)oxazolo(4,5-b)pyridin-6-yl)-2-(2-methylpyridin-4- Yl)-1,3-oxazole-4-carboxamide
14. N-[5-[(3r)-3-hydroxy-1-pyrrolidinyl]-2-(4-morpholinyl)oxazolo[4,5-b]pyridin-6-yl]-2-(2-methyl-4-pyridinyl)-4-oxazolecarboxamide
15. Emavusertib [usan]
16. Unii-mh5dmf9jky
17. Emavusertib(ca-4948)
18. Emavusertib (ca-4948)
19. Schembl16896638
20. Gtpl10152
21. Dtxsid001103300
22. Ex-a4736
23. Au4948
24. Bdbm50547964
25. Nsc824184
26. S9779
27. Who 11558
28. Nsc-824184
29. Compound 24 [pmid: 33335659]
30. Ac-36757
31. Hy-135317
32. Cs-0111301
33. A937061
34. Fj0
| Molecular Weight | 491.5 g/mol |
|---|---|
| Molecular Formula | C24H25N7O5 |
| XLogP3 | 1.7 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 5 |
| Exact Mass | 491.19171692 g/mol |
| Monoisotopic Mass | 491.19171692 g/mol |
| Topological Polar Surface Area | 143 Ų |
| Heavy Atom Count | 36 |
| Formal Charge | 0 |
| Complexity | 773 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Emavusertib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Emavusertib, including repackagers and relabelers. The FDA regulates Emavusertib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Emavusertib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Emavusertib supplier is an individual or a company that provides Emavusertib active pharmaceutical ingredient (API) or Emavusertib finished formulations upon request. The Emavusertib suppliers may include Emavusertib API manufacturers, exporters, distributors and traders.
Emavusertib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Emavusertib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Emavusertib GMP manufacturer or Emavusertib GMP API supplier for your needs.
A Emavusertib CoA (Certificate of Analysis) is a formal document that attests to Emavusertib's compliance with Emavusertib specifications and serves as a tool for batch-level quality control.
Emavusertib CoA mostly includes findings from lab analyses of a specific batch. For each Emavusertib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Emavusertib may be tested according to a variety of international standards, such as European Pharmacopoeia (Emavusertib EP), Emavusertib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Emavusertib USP).
LOOKING FOR A SUPPLIER?
